576 related articles for article (PubMed ID: 19152408)
1. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
2. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
4. [Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
Wu ZP; Hang T; Gao YT; Li Y; Liu T; Jing L; Liu L; Du Z
Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):498-501. PubMed ID: 20678438
[TBL] [Abstract][Full Text] [Related]
5. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
8. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
9. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
[TBL] [Abstract][Full Text] [Related]
10. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.
Yatsuji H; Suzuki F; Sezaki H; Akuta N; Suzuki Y; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Watahiki S; Iwasaki S; Kobayashi M; Kumada H
J Hepatol; 2008 Jun; 48(6):923-31. PubMed ID: 18433925
[TBL] [Abstract][Full Text] [Related]
11. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
[TBL] [Abstract][Full Text] [Related]
12. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
14. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
15. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
16. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
[TBL] [Abstract][Full Text] [Related]
17. [A case of chronic hepatitis B with primary adefovir resistance].
Yamazhan T; Sertöz R; Pullukçu H; Taşbakan M; Ulusoy S; Erensoy S
Mikrobiyol Bul; 2007 Apr; 41(2):297-301. PubMed ID: 17682718
[TBL] [Abstract][Full Text] [Related]
18. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
[TBL] [Abstract][Full Text] [Related]
19. [The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].
Qin YL; Zhang JM; Huang YX; Mao RC; Yin YK; Zhang WQ; Zhang QB; Wu XH; Weng XH
Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):4-7. PubMed ID: 17244449
[TBL] [Abstract][Full Text] [Related]
20. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression.
Leemans WF; Janssen HL; Niesters HG; de Man RA
J Viral Hepat; 2008 Feb; 15(2):108-14. PubMed ID: 18184193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
